Hussman Strategic Advisors Inc. Acquires 16,800 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Hussman Strategic Advisors Inc. boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 200.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,200 shares of the company's stock after purchasing an additional 16,800 shares during the period. Hussman Strategic Advisors Inc.'s holdings in Neurocrine Biosciences were worth $2,787,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in NBIX. Huntington National Bank lifted its stake in Neurocrine Biosciences by 73.5% during the fourth quarter. Huntington National Bank now owns 229 shares of the company's stock worth $31,000 after purchasing an additional 97 shares during the period. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Neurocrine Biosciences during the first quarter worth approximately $34,000. GeoWealth Management LLC increased its holdings in shares of Neurocrine Biosciences by 65.4% during the fourth quarter. GeoWealth Management LLC now owns 258 shares of the company's stock worth $35,000 after buying an additional 102 shares in the last quarter. Golden State Wealth Management LLC increased its holdings in shares of Neurocrine Biosciences by 116.9% in the first quarter. Golden State Wealth Management LLC now owns 397 shares of the company's stock valued at $44,000 after purchasing an additional 214 shares in the last quarter. Finally, Versant Capital Management Inc increased its holdings in shares of Neurocrine Biosciences by 404.9% in the first quarter. Versant Capital Management Inc now owns 409 shares of the company's stock valued at $45,000 after purchasing an additional 328 shares in the last quarter. Institutional investors own 92.59% of the company's stock.

Insider Buying and Selling at Neurocrine Biosciences

In related news, Director Kevin Charles Gorman sold 9,613 shares of Neurocrine Biosciences stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $120.38, for a total transaction of $1,157,212.94. Following the completion of the transaction, the director owned 514,596 shares of the company's stock, valued at $61,947,066.48. This trade represents a 1.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William H. Rastetter sold 30,000 shares of Neurocrine Biosciences stock in a transaction on Monday, May 5th. The stock was sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the transaction, the director directly owned 37,491 shares of the company's stock, valued at $4,131,508.20. This represents a 44.45% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 120,251 shares of company stock worth $14,978,602 in the last three months. 4.80% of the stock is currently owned by company insiders.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX traded down $0.76 during trading hours on Friday, hitting $133.35. 70,451 shares of the stock were exchanged, compared to its average volume of 1,142,365. The company has a market cap of $13.20 billion, a PE ratio of 45.19, a price-to-earnings-growth ratio of 1.37 and a beta of 0.24. The company's fifty day simple moving average is $125.18 and its two-hundred day simple moving average is $121.53. Neurocrine Biosciences, Inc. has a 1-year low of $84.23 and a 1-year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). The company had revenue of $572.60 million during the quarter, compared to analyst estimates of $587.06 million. Neurocrine Biosciences had a net margin of 12.68% and a return on equity of 11.81%. The business's quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.20 EPS. As a group, sell-side analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on NBIX. Wedbush reissued an "outperform" rating on shares of Neurocrine Biosciences in a report on Tuesday, May 6th. HC Wainwright lowered their target price on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating for the company in a report on Tuesday, April 22nd. Wall Street Zen lowered shares of Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Thursday, March 20th. The Goldman Sachs Group initiated coverage on shares of Neurocrine Biosciences in a report on Thursday, July 10th. They issued a "buy" rating and a $182.00 price target for the company. Finally, JPMorgan Chase & Co. boosted their price target on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the company an "overweight" rating in a report on Wednesday, March 26th. Three research analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the stock. According to data from MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of "Moderate Buy" and an average target price of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.